Kevin Fischbeck

Joel framed IKC growth as more than a margin story, emphasizing continued expansion in lives and dollars under management with room to run for a while.

Joel said the pickup is complete and tied solely to the 100 clinics Fresenius closed, with no further change expected this year.

CFO attributed ~$6 of the $17.50 year-over-year RPT increase to timing (negative timing in Q1 2025 plus positive timing in Q1 2026). Remaining 2/3 from normal rate increases and mix shifts. Sticking with 1-2% full-year guide.

CEO confirmed commercial mix was flat Q4 to Q1, better than expected. However, effectuation rates and actual payment behavior are unknown in the first post-subsidy cycle. Maintaining $40M headwind assumption but trending slightly better.

CFO said weather was ~10bps better than last year but in line with forecast. Flu impact also as expected (modeled on 2-year-ago season). The mortality improvement was from underlying trends, not flu, since flu came in as expected.

CFO confirmed free cash flow guidance is before the $200M Elara investment, and no other major capital uses beyond share repurchases. Leverage at midpoint of 3-3.5x range provides room for additional buyback capacity from EBITDA growth.

CEO framed volume recovery as fundamentally a clinical story requiring mortality improvement. Estimated initial benefits in approximately 2 years with full effect by 2029. Cited vaccination, GLP-1s, middle molecules, and home care as key levers.

CEO confirmed the 3-7% OI growth and 8-14% EPS growth targets are framed as approximately 3-year commitments.

CEO framed mortality improvement as a long-term clinical effort across multiple protocol areas including time on therapy, fluid management, GLP-1s, and eventually middle-molecule clearance.

CEO explained two dynamics: MA membership shifts between payers with different rates, and enhanced premium tax credit expiration affecting open enrollment commercial mix. CFO clarified commercial mix is a more significant financial swing factor than MA mix.

CFO quantified the combined volume headwind from hurricane, cyber, and flu at 75-100bps, covering both census and missed treatment rate impacts.

CEO confirmed no inherent roadblock to maintaining cost control if volumes grow, suggesting potential for upside above the 3-7% OI growth range, though declined to commit specifically.

Management attributed elevated mortality to COVID holdover effects including delayed care and higher comorbidity acuity. Emphasized this is a national all-cause trend, not kidney-specific.

Tim Noel rejected the acceleration premise, citing moderation in government programs, commercial stabilization north of 11%, and real-time data in pricing.

DeVeydt confirmed $19.50 to $20 as the stepping off point and acknowledged it includes prior period development, but asserted the run rate is durable.

Tim described tools for early identification of outlier patterns, leaning toward HMO products for better management, network actions taken. Did not size the acuity component specifically, deferring granularity to Q2.

Noel said coding component impact consistent with industry averages. Nelson cited Texas market example with 750,000 patients showing total cost of care approximately 30% better than competitors, NPS of 90, and margins already in target range. About 30% of mature VBC patients already inside or above target margin range.

Nelson said VBC potential is limitless but current focus is on operating discipline and returning to core. Hemsley added alignment to right products, processes and disciplines is what they are returning to. No specific TAM quantification provided.

Hemsley said prior management pursued portfolio re-evaluation and divestitures which he stopped entirely. His orientation is to run existing businesses to full potential first. Removed all portfolio action assumptions from outlook. Will pick up portfolio assessment later but current focus is on performance of existing businesses.

Ann reaffirmed ~$9B operating cash flow (back-half weighted) and on-plan Signature transition spend; Brian called the risk-book transition 'very smooth' so far. Direct.

Brian confirmed both were proactive decisions driven by lack of scale and management focus redirection. Capital freed from exchange exit characterized as immaterial in context of overall company.

Ann walked through MCR bridge: reductions from stop-loss pricing and exchange repricing, offset by absence of 2025 one-time individual business items and mix dynamics. Appropriate prudence given continued elevated cost environment.

Brian confirmed investment spend broadly consistent 2026-2027, not an incremental year-over-year headwind. Described substantial technology investments (market-facing and back-office) plus recontracting with manufacturers, pharmacies, and clients. David added enterprise expected back on algorithm for 2027.

Brian described firm pricing market with no competitor appetite to underprice. 2026 price increases expected to exceed 2025. Ann noted exchange business and stop-loss as two exceptions running below target margins.

London conceded the acuity dislocation will mute near-term margin recovery and put the inflection in the back half of 2027, with Asher adding expansion-population detail.

Sarah detailed deceleration in behavioral health units per utilizer reflecting state benefit sophistication and provider evidence-based guidelines adoption. ABA trends stabilizing year over year as direct result of 12+ months of intervention. Not huge abatement but trend lapse, no continued year-over-year steps. Acuity shift from redetermination attrition (~1-1.5% per quarter) embedded in net 4.5% trend assumption for 2026.

Sarah walked through confidence sources: Q3 repricing incorporated baseline morbidity, trend, risk pool shifts, and eAPTC expiry into mid-30s rate increase. February paid membership tracking in line with expectations. Bronze over 30% versus 19-24% historical but pre-eAPTC bronze data informs underwriting. Low-cost bronze footprint reduced year over year.

Sarah confirmed goal of consistent margin improvement over next couple of years toward normalized levels. Work requirements impacts most likely in 2027-2028, with CMS guidance not scheduled until summer, making 1/1/27 earliest implementation.

Sarah confirmed Medicaid margin recovery is 'when, not if' over next 4-6 quarters. Will need to account for OB3 work requirements and 6-month verifications impacting risk pool in 2027-2028.

Mark said July rate updates were mid-single-digit but the full-year benefit is moderated by timing and book coverage, so the margin outlook is held prudent on elevated utilization; Gail framed exits as long-term portfolio discipline.

Mark addressed risk pool concerns directly. Prior claims for renewing members running moderately higher than cancel cohorts, supporting view that attrition increased pool morbidity, but tracking consistent with or better than pricing assumptions.

Gail pushed back firmly that membership declines reflect disciplined decisions not competitive weakness: ACA repositioned sustainably, commercial had conscious pricing decisions on below-profitability public sector, ASO had strong national account selling, Medicaid reflects redetermination, MA positioned for sustainable margin growth.

Mark described margin decline as more balanced split between acuity and utilization versus prior quarter. On 2027 balanced growth, confirmed it means returning to the historical growth algorithm with contributions from Commercial, government, and Carelon supported by operating leverage.

Gail maintained Medicaid is a core strategic franchise with short-term volatility. Acknowledged work requirements create new unknowns but emphasized state partnerships and commercial capabilities.

Explained the return-based plan selection and noted most exits were in plans rated 3.5 or lower, while stating this is not a Stars-driven decision.

James confirmed gap between funding and medical cost trend is clearly larger than prior year. Other operational levers on track. Difference is funding environment relative to cost trend, which has been stable for 2 years. George added HUM was adjusting benefits 2 years before most competitors.

James said April/May views are early enough to adjust bids. Priorities clearly ordered: #1 margin trajectory for 2028, #2 retention within margin constraints, #3 growth is a distant third. New member growth is not the focus.

James outlined four factors: attrition/retention rates, cost of acquisition, engagement rates (Stars, diagnosis accuracy), all varying by channel. Reduced plan-to-plan sales correlates with better retention.

Celeste confirmed Part D tracking in line. George added PDP developing as expected, co-pay vs coinsurance structure working. 2026 national average bid slightly better than expected.